FDA Removes Top Expert on Vaping and Tobacco

Follow Drugslib on

Medically reviewed by Carmen Pope, BPharm. Last updated on April 2, 2025.

By I. Edwards HealthDay Reporter

WEDNESDAY, April 2, 2025 -- The U.S. Food and Drug Administration’s (FDA) top tobacco regulator, Brian King, has been placed on leave as part of a large wave of cuts across federal health agencies.

King, who led the FDA's tobacco control efforts, told his staff Tuesday that he was removed with “a heavy heart and profound disappointment.”

“If you make it virtually impossible to create and draft policy, then you are eviscerating the role of the center,” Mitch Zeller, the FDA’s former tobacco chief, said in an interview with The Associated Press. “From a public health perspective it makes absolutely no sense.”

King joined the FDA in 2022 and became a target of vaping industry criticism for ordering thousands of flavored e-cigarettes off the market. During his tenure, teen vaping dropped to its lowest level in 10 years.

His removal follows the recent resignation of vaccine chief Dr. Peter Marks, who said he could no longer support the Trump administration’s promotion of vaccine misinformation.

The FDA has seen a major leadership turnover in recent months. Top officials overseeing drugs, food, vaccines and medical devices have either resigned or retired. In an online post, former FDA Commissioner Robert Califf said “history will see this as a huge mistake,” The Associated Press reported.

“The FDA as we’ve known it is finished, with most of the leaders with institutional knowledge and a deep understanding of product development and safety no longer employed,” Califf, who stepped down at the end of the Biden administration, said.

The cuts dovetail with a push by U.S. Health Secretary Robert F. Kennedy Jr. to fire 3,500 FDA workers and investigate common products like vaccines, antidepressants and ultraprocessed foods.

New FDA Commissioner Marty Makary now goes to work with many of his agency’s top experts gone and employees rattled with uncertainty.

Makary told senators during his confirmation hearing that he plans to “conduct an assessment” of the recent job cuts.

The FDA’s tobacco center has faced pressure from politicians, parents, as well as anti-tobacco groups.

Critics say the agency has been too slow to approve low-risk products for adults, while anti-vaping advocates say more should be done to stop illegal products aimed at kids and teens.

While smoking rates are at historic lows, tobacco-related diseases still kill over 480,000 Americans each year, according to the U.S. Centers for Disease Control and Prevention. E-cigarettes were once promoted as a tool to help people quit tobacco.

Under King’s leadership, the FDA rejected millions of flavored e-cigarettes, saying there wasn’t enough evidence they helped adult smokers quit, according to The Associated Press.

The Vapor Technology Association, a group representing vape companies, called King’s removal "the first step in correcting the broken mindset that has crippled the FDA and the Center for Tobacco Products over the past four years.”

Sources

  • The Associated Press, April 1, 2025

    • Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

    Source: HealthDay

    Posted : 2025-04-03 06:00

    Read more

    Disclaimer

    Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

    The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.

    Popular Keywords